The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience

Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health policy (Amsterdam) 2008-08, Vol.87 (2), p.217-222
Hauptverfasser: Risha, Peter Gasper, Msuya, Zera, Clark, Malcolm, Johnson, Keith, Ndomondo-Sigonda, Margareth, Layloff, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 222
container_issue 2
container_start_page 217
container_title Health policy (Amsterdam)
container_volume 87
creator Risha, Peter Gasper
Msuya, Zera
Clark, Malcolm
Johnson, Keith
Ndomondo-Sigonda, Margareth
Layloff, Thomas
description Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.
doi_str_mv 10.1016/j.healthpol.2007.12.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69274602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0168851008000067</els_id><sourcerecordid>69274602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</originalsourceid><addsrcrecordid>eNqNksuO1DAQRSMEYpqBXwCv2HXwI4kdFkij0fDSIBY0a8txKhM3eWE7LcKSD-Ij-DIqdGuQ2AwLuyz53FKV7k2SZ4ymjLLixT5twXSxncYu5ZTKlPGUMnov2TAl-bageXY_2SCptipn9Cx5FMKeIihE8TA5Y4orXgi-SX7sWiBzADI25IMbXGeq8OsniSNx_eTHA5CIQIQQ3XBDrJmMdXFZaQ83c2fi6Bdi5tiO3kUHgbgBf8I4ewukc72LUJMAcZWHl2Rnhu9mcGYg8G0C72Cw8Dh50JguwJNTPU8-v77aXb7dXn988-7y4npr81zEreV1RYWlmeCVzWvIcVMQrDLGVKooKsPrWpWZUGWZNSXjuGuWWZ4rLhvOGynOk-fHvrjX1xk30r0LFrrODDDOQRcll1lB-Z1gLrlQUtwNiqLMSiUEgvIIWj-G4KHRk3e98YtmVK-G6r2-NVSvhmrGNRqKyvdHpYcJ7K0MAFpA1umDFkZJvBY8qFRY3PrEM62VSc05123ssdnT07xz1UP9d4hTHBC4OAKAPhwceB3sH49q58FGXY_uPyZ-9U8P22GwrOm-wAJhj9EY0GbNdECB_rSGdM0oVZhPWkjxGw015qA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>36949833</pqid></control><display><type>article</type><title>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>MEDLINE</source><source>RePEc</source><source>Access via ScienceDirect (Elsevier)</source><creator>Risha, Peter Gasper ; Msuya, Zera ; Clark, Malcolm ; Johnson, Keith ; Ndomondo-Sigonda, Margareth ; Layloff, Thomas</creator><creatorcontrib>Risha, Peter Gasper ; Msuya, Zera ; Clark, Malcolm ; Johnson, Keith ; Ndomondo-Sigonda, Margareth ; Layloff, Thomas</creatorcontrib><description>Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.</description><identifier>ISSN: 0168-8510</identifier><identifier>EISSN: 1872-6054</identifier><identifier>DOI: 10.1016/j.healthpol.2007.12.010</identifier><identifier>PMID: 18282632</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Capacity ; Chromatography, Thin Layer - instrumentation ; Decision Trees ; Drug Contamination - prevention &amp; control ; Drug Industry - standards ; Drug Prescriptions - standards ; Drugs ; Government Regulation ; Health administration ; Health Resources ; Humans ; Imports ; Instillation, Drug ; Internal Medicine ; Internationality ; Minilab ; Monitoring ; Pharmaceuticals ; Product Surveillance, Postmarketing - methods ; Program Evaluation ; Public Health Administration - methods ; Quality assurance ; Quality Control ; Quality standards ; Regulation ; Screening ; Software Design ; Substandard ; Substandard drugs ; Tanzania ; Testing-capacity</subject><ispartof>Health policy (Amsterdam), 2008-08, Vol.87 (2), p.217-222</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2008 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</citedby><cites>FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.healthpol.2007.12.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,4012,27933,27934,31009,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18282632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/eeehepoli/v_3a87_3ay_3a2008_3ai_3a2_3ap_3a217-222.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Risha, Peter Gasper</creatorcontrib><creatorcontrib>Msuya, Zera</creatorcontrib><creatorcontrib>Clark, Malcolm</creatorcontrib><creatorcontrib>Johnson, Keith</creatorcontrib><creatorcontrib>Ndomondo-Sigonda, Margareth</creatorcontrib><creatorcontrib>Layloff, Thomas</creatorcontrib><title>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</title><title>Health policy (Amsterdam)</title><addtitle>Health Policy</addtitle><description>Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.</description><subject>Capacity</subject><subject>Chromatography, Thin Layer - instrumentation</subject><subject>Decision Trees</subject><subject>Drug Contamination - prevention &amp; control</subject><subject>Drug Industry - standards</subject><subject>Drug Prescriptions - standards</subject><subject>Drugs</subject><subject>Government Regulation</subject><subject>Health administration</subject><subject>Health Resources</subject><subject>Humans</subject><subject>Imports</subject><subject>Instillation, Drug</subject><subject>Internal Medicine</subject><subject>Internationality</subject><subject>Minilab</subject><subject>Monitoring</subject><subject>Pharmaceuticals</subject><subject>Product Surveillance, Postmarketing - methods</subject><subject>Program Evaluation</subject><subject>Public Health Administration - methods</subject><subject>Quality assurance</subject><subject>Quality Control</subject><subject>Quality standards</subject><subject>Regulation</subject><subject>Screening</subject><subject>Software Design</subject><subject>Substandard</subject><subject>Substandard drugs</subject><subject>Tanzania</subject><subject>Testing-capacity</subject><issn>0168-8510</issn><issn>1872-6054</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><sourceid>7QJ</sourceid><recordid>eNqNksuO1DAQRSMEYpqBXwCv2HXwI4kdFkij0fDSIBY0a8txKhM3eWE7LcKSD-Ij-DIqdGuQ2AwLuyz53FKV7k2SZ4ymjLLixT5twXSxncYu5ZTKlPGUMnov2TAl-bageXY_2SCptipn9Cx5FMKeIihE8TA5Y4orXgi-SX7sWiBzADI25IMbXGeq8OsniSNx_eTHA5CIQIQQ3XBDrJmMdXFZaQ83c2fi6Bdi5tiO3kUHgbgBf8I4ewukc72LUJMAcZWHl2Rnhu9mcGYg8G0C72Cw8Dh50JguwJNTPU8-v77aXb7dXn988-7y4npr81zEreV1RYWlmeCVzWvIcVMQrDLGVKooKsPrWpWZUGWZNSXjuGuWWZ4rLhvOGynOk-fHvrjX1xk30r0LFrrODDDOQRcll1lB-Z1gLrlQUtwNiqLMSiUEgvIIWj-G4KHRk3e98YtmVK-G6r2-NVSvhmrGNRqKyvdHpYcJ7K0MAFpA1umDFkZJvBY8qFRY3PrEM62VSc05123ssdnT07xz1UP9d4hTHBC4OAKAPhwceB3sH49q58FGXY_uPyZ-9U8P22GwrOm-wAJhj9EY0GbNdECB_rSGdM0oVZhPWkjxGw015qA</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Risha, Peter Gasper</creator><creator>Msuya, Zera</creator><creator>Clark, Malcolm</creator><creator>Johnson, Keith</creator><creator>Ndomondo-Sigonda, Margareth</creator><creator>Layloff, Thomas</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8BJ</scope><scope>FQK</scope><scope>JBE</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>20080801</creationdate><title>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</title><author>Risha, Peter Gasper ; Msuya, Zera ; Clark, Malcolm ; Johnson, Keith ; Ndomondo-Sigonda, Margareth ; Layloff, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Capacity</topic><topic>Chromatography, Thin Layer - instrumentation</topic><topic>Decision Trees</topic><topic>Drug Contamination - prevention &amp; control</topic><topic>Drug Industry - standards</topic><topic>Drug Prescriptions - standards</topic><topic>Drugs</topic><topic>Government Regulation</topic><topic>Health administration</topic><topic>Health Resources</topic><topic>Humans</topic><topic>Imports</topic><topic>Instillation, Drug</topic><topic>Internal Medicine</topic><topic>Internationality</topic><topic>Minilab</topic><topic>Monitoring</topic><topic>Pharmaceuticals</topic><topic>Product Surveillance, Postmarketing - methods</topic><topic>Program Evaluation</topic><topic>Public Health Administration - methods</topic><topic>Quality assurance</topic><topic>Quality Control</topic><topic>Quality standards</topic><topic>Regulation</topic><topic>Screening</topic><topic>Software Design</topic><topic>Substandard</topic><topic>Substandard drugs</topic><topic>Tanzania</topic><topic>Testing-capacity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Risha, Peter Gasper</creatorcontrib><creatorcontrib>Msuya, Zera</creatorcontrib><creatorcontrib>Clark, Malcolm</creatorcontrib><creatorcontrib>Johnson, Keith</creatorcontrib><creatorcontrib>Ndomondo-Sigonda, Margareth</creatorcontrib><creatorcontrib>Layloff, Thomas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Health policy (Amsterdam)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Risha, Peter Gasper</au><au>Msuya, Zera</au><au>Clark, Malcolm</au><au>Johnson, Keith</au><au>Ndomondo-Sigonda, Margareth</au><au>Layloff, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</atitle><jtitle>Health policy (Amsterdam)</jtitle><addtitle>Health Policy</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>87</volume><issue>2</issue><spage>217</spage><epage>222</epage><pages>217-222</pages><issn>0168-8510</issn><eissn>1872-6054</eissn><abstract>Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>18282632</pmid><doi>10.1016/j.healthpol.2007.12.010</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-8510
ispartof Health policy (Amsterdam), 2008-08, Vol.87 (2), p.217-222
issn 0168-8510
1872-6054
language eng
recordid cdi_proquest_miscellaneous_69274602
source Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; RePEc; Access via ScienceDirect (Elsevier)
subjects Capacity
Chromatography, Thin Layer - instrumentation
Decision Trees
Drug Contamination - prevention & control
Drug Industry - standards
Drug Prescriptions - standards
Drugs
Government Regulation
Health administration
Health Resources
Humans
Imports
Instillation, Drug
Internal Medicine
Internationality
Minilab
Monitoring
Pharmaceuticals
Product Surveillance, Postmarketing - methods
Program Evaluation
Public Health Administration - methods
Quality assurance
Quality Control
Quality standards
Regulation
Screening
Software Design
Substandard
Substandard drugs
Tanzania
Testing-capacity
title The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T06%3A31%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20Minilabs%C2%AE%20to%20improve%20the%20testing%20capacity%20of%20regulatory%20authorities%20in%20resource%20limited%20settings:%20Tanzanian%20experience&rft.jtitle=Health%20policy%20(Amsterdam)&rft.au=Risha,%20Peter%20Gasper&rft.date=2008-08-01&rft.volume=87&rft.issue=2&rft.spage=217&rft.epage=222&rft.pages=217-222&rft.issn=0168-8510&rft.eissn=1872-6054&rft_id=info:doi/10.1016/j.healthpol.2007.12.010&rft_dat=%3Cproquest_cross%3E69274602%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=36949833&rft_id=info:pmid/18282632&rft_els_id=1_s2_0_S0168851008000067&rfr_iscdi=true